Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $541.0052W HIGH $859.34
Volume
466.03 K
Value Traded
976.93 M
Short % Float
2.55%
+2.76%Week
-5.89%1 Month
+12.59%3 Month
+0.01%6 Month
+24.26%5 Year
+2,924.28%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
76.86 B
EPS (TTM)
42.04
P/E Ratio
17.76
Ent. Value
61.02 B
Total Shares
102.95 M
Float Shares
99.07 M
Insiders
3.78%
Institutions
91.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
REGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Regeneron Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Regeneron Pharmaceuticals, Inc.
1388Total events
29Upcoming
708Tier-1 (high impact)
2011 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Primary Endpoint MetTrevogrumabClinical Data
Lower-dose trevogrumab met primary endpoint of lean mass preservation at 26 and 52 weeks vs placebo
obesity (lean mass preservation during semaglutide-induced weight loss)source ↗
▲Topline ReadoutTrevogrumabClinical Data
Phase 2 COURAGE trial results for trevogrumab presented at EASD and in press with The Lancet
obesity (lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss)source ↗
▲Biomarker DataTrevogrumabClinical Data
MRI substudy: trevogrumab prevented ~70% of thigh muscle loss associated with semaglutide
obesity (muscle volume by MRI)source ↗
▲Subgroup AnalysisTrevogrumabClinical Data
Pre-specified subgroup analysis: patients with low lean mass had greater lean mass preservation with trevogrumab
obesity with low lean mass (sarcopenia definition)source ↗
▲Safety Data UpdateTrevogrumabClinical Data
Lower doses of trevogrumab generally well tolerated; 77% AE rate vs 82% placebo
obesitysource ↗
●Oral PresentationTrevogrumabPresentation
COURAGE results presented during Scientific Symposium at EASD Annual Meeting
obesitysource ↗
●Topline ReadoutOlatorepatideClinical Data
Hansoh presented Phase 3 data for olatorepatide in Chinese patients with obesity or overweight
obesity or overweightsource ↗
▲Oral PresentationUbamatamabPresentation
Late-breaking plenary oral presentation of ubamatamab LGSOC data at IGCS 2026
low-grade serous ovarian cancer (LGSOC)source ↗
▲Topline ReadoutUbamatamabClinical Data
Initial Phase 1/2 results for ubamatamab in LGSOC presented at IGCS 2026
low-grade serous ovarian cancer (LGSOC)source ↗
●Oral PresentationOlatorepatidePresentation
Hansoh presented Phase 3 data for olatorepatide in Chinese patients with obesity or overweight at EASD
obesity or overweightsource ↗
▲Late-BreakerCemiplimabApprovedPresentation
Late-breaking Phase 3 C-POST longer-term OS data for adjuvant Libtayo in high-risk CSCC presented at ESMO 2026
high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiationsource ↗
◆PDUFA DateGaretosmabApprovedRegulatory Filing
FDA accepted BLA for garetosmab with target action date in August 2026
fibrodysplasia ossificans progressiva (FOP)source ↗
◆Oral PresentationlinvoseltamabApprovedPresentation
First results from LINKER-AL2 to be presented at ASCO 2026
systemic amyloid light chain (AL) amyloidosissource ↗
▲Other Regulator MilestonemaftivimabEx-US Regulatory
WHO Therapeutics Advisory Group recommends maftivimab for evaluation in clinical trials
Bundibugyo ebolavirus infectionsource ↗
▲EU MAA SubmissionOtarmeni™ApprovedEx-US Regulatory
EMA accepts MAA for Otarmeni under Accelerated Assessment
biallelic OTOF variant-associated hearing losssource ↗
▲EMA Accelerated AssessmentOtarmeni™ApprovedEx-US Regulatory
Accelerated Assessment granted by EMA for Otarmeni MAA
biallelic OTOF variant-associated hearing losssource ↗
▲EMA ValidationOtarmeni™ApprovedEx-US Regulatory
EMA accepted MAA for Otarmeni under Accelerated Assessment
biallelic OTOF variant-associated hearing losssource ↗
▲Topline ReadoutlinvoseltamabApprovedClinical Data
Preliminary analysis results from LINKER-AL2: 100% hematologic CR at highest dose
systemic amyloid light chain (AL) amyloidosissource ↗
●Trial InitiationlinvoseltamabApprovedTrial
Phase 2 portion of LINKER-AL2 with registrational intent is ongoing
systemic amyloid light chain (AL) amyloidosissource ↗
▲Oral PresentationdupilumabApprovedPresentation
Late-breaking oral presentation of REMODEL Phase 4 results at DDW 2026
eosinophilic esophagitissource ↗
▲Topline ReadoutdupilumabApprovedClinical Data
REMODEL Phase 4 trial meets primary endpoint of improved esophageal distensibility at week 24
eosinophilic esophagitissource ↗
▲Primary Endpoint MetdupilumabApprovedClinical Data
Primary endpoint met: esophageal distensibility plateau improvement
Eosinophilic Esophagitissource ↗
▲Full ResultsdupilumabApprovedClinical Data
Full results of REMODEL Phase 4 trial presented at DDW
Eosinophilic Esophagitissource ↗
◆EU ApprovaldupilumabApprovedEx-US Regulatory
Final EU decision on Dupixent for CSU in children expected
chronic spontaneous urticaria (CSU)source ↗
▲FDA ApprovalOtarmeni™ApprovedFDA Decision
FDA granted accelerated approval for Otarmeni
severe-to-profound and profound sensorineural hearing loss associated with biallelic variants in the OTOF genesource ↗
▲Product LaunchOtarmeni™ApprovedPost-Market
Regeneron will provide Otarmeni for free in the U.S.
severe to profound and profound hearing loss due to variants of the otoferlin genesource ↗
●Quarterly UpdateCorporate
Future U.S. prices aligned with prices in defined group of other countries
▲Primary Endpoint MetOtarmeni™ApprovedClinical Data
80% of participants achieved or surpassed primary endpoint hearing level; 42% achieved normal hearing with longer follow-up
OTOF-related hearing losssource ↗
▲FDA ApprovalOtarmeni™ApprovedFDA Decision
FDA approval of Otarmeni
severe to profound and profound hearing loss due to variants of the otoferlin genesource ↗
▲Product LaunchOtarmeni™ApprovedPost-Market
Otarmeni to be provided for free in the U.S.
severe to profound and profound hearing loss due to variants of the otoferlin genesource ↗
▲Product LaunchAlirocumabApprovedPost-Market
Praluent available for direct patient purchase through TrumpRx.gov
cardiovascularsource ↗
▲Manufacturing MilestoneCMC / Inspection
Commitment to invest over $9 billion in U.S.-based manufacturing and R&D infrastructure
▲Product LaunchOtarmeni™ApprovedPost-Market
Regeneron to provide Otarmeni for free in the U.S.
severe-to-profound and profound sensorineural hearing loss associated with biallelic variants in the OTOF genesource ↗
▲Topline ReadoutOtarmeni™ApprovedClinical Data
Pivotal results from CHORD trial reported
OTOF-related hearing losssource ↗
●Enrollment UpdateOtarmeni™ApprovedTrial
CHORD trial currently enrolling children (<18 years) across U.S., UK, Spain, Germany, Japan
OTOF-related hearing losssource ↗
▲EU ApprovaldupilumabApprovedEx-US Regulatory
EC approved Dupixent for CSU in children aged 2 to 11 years
chronic spontaneous urticaria (CSU)source ↗
▲FDA Filing AccepteddupilumabApprovedRegulatory Filing
sBLA accepted for review in US for children aged 2-11 years with CSU
chronic spontaneous urticariasource ↗
▲Partnership / LicenseCorporate
Regeneron and TriNetX announce strategic collaboration for EHR data access
▲FDA ApprovalOtarmeni™ApprovedFDA Decision
U.S. FDA accelerated approval of Otarmeni in April 2026
severe-to-profound and profound sensorineural hearing loss associated with biallelic OTOF variantssource ↗
◆Timing GuidancedupilumabApprovedPresentation
FDA decision expected by April 2026 for Dupixent sBLA in CSU children
chronic spontaneous urticaria (CSU)source ↗
▲FDA ApprovalAfliberceptApprovedFDA Decision
FDA approved extension of dosing intervals for EYLEA HD up to every 20 weeks
wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)source ↗
▲FDA ApprovaldupilumabApprovedFDA Decision
FDA and EC approved Dupixent for CSU in children aged 2 to 11 years
chronic spontaneous urticaria (CSU) in children aged 2 to 11 yearssource ↗
▲EU ApprovaldupilumabApprovedEx-US Regulatory
EC approved Dupixent for CSU in children aged 2 to 11 years
chronic spontaneous urticaria (CSU) in children aged 2 to 11 yearssource ↗
◆Timing GuidanceCemdisiranFiledPresentation
NDA acceptance for cemdisiran anticipated
myasthenia gravissource ↗
◆Topline ReadoutFianlimabFiledClinical Data
Results from Phase 3 study of fianlimab in combination with cemiplimab versus pembrolizumab in first-line metastatic melanoma
first-line metastatic melanomasource ↗
Past FDA Catalysts and PDUFA Decisions
How REGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | pozelimab | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A80 / 100
Pipeline Score
$24.9B
Pipeline Value
$66.5B
Commercial Value
Fair Value
Valuation Signal
68
Drugs Scored
1.1x
rNPV / MCap
Top 2%
Large Pharma(rank 14 of 660)
Percentile Rank
Regeneron Pharmaceuticals, Inc. earns an A-grade pipeline score (80/100), with $24.9B risk-adjusted pipeline value, led by REGN7508 in Venous Thromboembolism (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $15.5B x 4.3 = $66.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| EYLEA | $2.1B | $3.8B | -44% |
| EYLEA HD | $2.0B | $1.4B | +43.3% |
| LIBTAYO | $1.7B | $1.3B | +30.5% |
| Praluent | $281M | $238M | +18.1% |
| Evkeeza | $189M | $143M | +32.6% |
| Lynozyfic | $28M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN7508 Small moleculeNCT07318610 | Peripheral Artery Disease (PAD) | Phase 3 | RECRUITING | 7,050 | Nov 16, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every REGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Libtayo | cutaneous squamous cell carcinoma | Phase 3 | 2026-10-06 | Late-breaking overall survival (OS) data at approximately 3.5 years follow-up from the C-POST Phase 3 trialRead More | Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McCourt MarionOfficer (EVP Commercial) | Sell | -1,131 12,003 held | $857.39 | 09/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in REGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1 % (-67.7 %) | 24.94 M | 40.00 K | -52.94% ( -45.00 K) |
REGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How REGN ranks across every disease it competes in
Competitive Position is a premium feature
See how REGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialREGN News
REGNRegeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Regeneron Pharmaceuticals presented new clinical research at the ESMO Congress 2026, highlighting advancements in cancer treatment, particularly with Libtayo for cutaneous squamous cell carcinoma (CSCC). The data includes late-breaking Phase 3 results demonstrating improved survival outcomes and a Phase 2 analysis of neoadjuvant treatment. Additionally, new approaches to manage cancer-associated thrombosis were discussed.
Read more →REGNUbamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Regeneron Pharmaceuticals announced promising results for ubamatamab in patients with advanced low-grade serous ovarian cancer (LGSOC). In a Phase 1/2 trial, the drug demonstrated a 73% objective response rate and an 11-month median progression-free survival. Regeneron plans to advance ubamatamab into a confirmatory Phase 3 trial, aiming to address the unmet needs in this challenging cancer subtype.
Read more →REGNPhase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Regeneron Pharmaceuticals announced positive results from the Phase 2 COURAGE trial, which demonstrated that trevogrumab can prevent significant muscle loss during GLP-1 receptor agonist-induced weight loss. The trial showed that trevogrumab preserved nearly 70% of muscle mass compared to semaglutide alone. These findings were presented at the EASD Annual Meeting and indicate potential for future clinical development.
Read more →REGNRegeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
Regeneron Pharmaceuticals, Inc. announced that it will report its third quarter 2026 financial and operating results on October 30, 2026. The company will also host a conference call and webcast at 8:30 AM ET on the same day. Participants can access the call via the company's website or by telephone after registering in advance.
Read more →REGNRegeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. These events will be webcasted, allowing broader access to management insights. Regeneron emphasizes its dedication to developing transformative medicines and leveraging proprietary technologies for drug development.
Read more →REGNPasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
Regeneron Pharmaceuticals announced FDA approval for Pasatru (garetosmab-grts), the first treatment for fibrodysplasia ossificans progressiva (FOP). The approval is based on the OPTIMA trial, which showed a 90% reduction in new heterotopic ossification lesions and a significant decrease in flare-ups. This treatment represents a crucial advancement for the approximately 900 individuals diagnosed with this ultra-rare condition.
Read more →REGNRegeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Regeneron Pharmaceuticals has awarded the 2026 Regeneron Prize for Creative Innovation to early-career scientists from NYU, Stanford, and Rensselaer Polytechnic Institute. The awards, totaling $150,000, recognize innovative proposals aimed at advancing biomedical research. Winners include Simon Vecchioni, Siyuan Du, and Frank Peters, each contributing unique projects with the potential to enhance human health.
Read more →REGN▲ +6.2%on this newsshared move
Regeneron Reports Second Quarter 2026 Financial and Operating Results
Regeneron Pharmaceuticals reported strong financial results for Q2 2026, with revenues rising 17% to $4.3 billion. Key products like Dupixent and EYLEA HD achieved record sales. The company also announced the acceptance of regulatory submissions for cemdisiran by the FDA and EMA. Overall, Regeneron continues to invest in its pipeline and manufacturing capabilities.
Read more →REGNRegeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
Regeneron Pharmaceuticals, Inc. will announce its second quarter 2026 financial and operating results on July 30, 2026. The announcement will be followed by a conference call and webcast at 8:30 AM Eastern Time. Participants can access the call via a registration link, and a replay will be available for 30 days.
Read more →REGNCemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Regeneron Pharmaceuticals announced that the FDA and EMA have accepted regulatory submissions for cemdisiran, a potential treatment for generalized myasthenia gravis (gMG). The FDA's Priority Review could lead to approval by November 2026, while a European decision is expected in late 2027. Cemdisiran, administered subcutaneously every 12 weeks, shows promise based on data from a significant Phase 3 trial.
Read more →REGNregeneron to highlight progress across its metabolic disease ophthalmology and rare disease pipelines at ada and endo
regeneron to highlight progress across its metabolic disease ophthalmology and rare disease pipelines at ada and endo
Read more →REGNRegeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Regeneron Pharmaceuticals announced that the World Health Organization has recommended maftivimab, a component of the Inmazeb cocktail, for evaluation in clinical trials targeting the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda. This recommendation follows the WHO's declaration of the outbreak as a public health emergency. Regeneron is coordinating efforts with health authorities to facilitate the trials and has existing supplies of Inmazeb available for immediate use.
Read more →REGNLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Regeneron Pharmaceuticals announced positive results from the Phase 1/2 LINKER-AL2 trial of Lynozyfic (linvoseltamab) for systemic AL amyloidosis. All patients treated achieved hematologic complete response, with significant organ function improvements noted. The trial is ongoing, with the Phase 2 segment aimed at further validating these findings. The investigational treatment shows promise for patients with limited options.
Read more →REGNOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Regeneron Pharmaceuticals announced that the European Medicines Agency has accepted the Marketing Authorization Application for Otarmeni (lunsotogene parvec), a gene therapy for biallelic OTOF variant-associated hearing loss. This acceptance under Accelerated Assessment could lead to Otarmeni being the first gene therapy approved for this condition in the EU. The application is backed by data from the CHORD clinical trial, which demonstrated the therapy's potential effectiveness.
Read more →REGN▼ -9.8%on this news
regeneron announces strategic collaboration with parabilis medicines to advance novel antibody helicon conjugates across multiple therapeutic areas
regeneron announces strategic collaboration with parabilis medicines to advance novel antibody helicon conjugates across multiple therapeutic areas
Read more →REGN▼ -9.8%on this newsshared move
regeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma
regeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma
Read more →REGNnext generation of scientific leaders awarded more than 7 million at the 2026 regeneron international science and engineering fair
next generation of scientific leaders awarded more than 7 million at the 2026 regeneron international science and engineering fair
Read more →REGNRegeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
Regeneron Pharmaceuticals has been named to the Dow Jones Best-in-Class World Index for corporate sustainability for seven consecutive years. The company also earned a spot on the North America Index for six years. This recognition highlights Regeneron's commitment to corporate responsibility, including offering a new gene therapy for free in the U.S. and setting ambitious 2030 responsibility goals.
Read more →REGNDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
Regeneron Pharmaceuticals and Sanofi announced positive results from the REMODEL Phase 4 trial of Dupixent (dupilumab) for eosinophilic esophagitis (EoE). At week 24, patients treated with Dupixent exhibited significant improvements in esophageal distensibility and reductions in disease-related structural changes compared to placebo. These findings highlight Dupixent's effectiveness in managing EoE symptoms and improving patient quality of life.
Read more →REGN▼ -6.2%on this news
Regeneron Reports First Quarter 2026 Financial and Operating Results
Regeneron Pharmaceuticals reported a 19% increase in revenues for Q1 2026, reaching $3.6 billion. Key products like Dupixent and EYLEA HD saw significant sales growth and received new FDA approvals. The company also announced a $3 billion share repurchase program. However, EYLEA HD faced a 10% decrease in net sales and ongoing regulatory challenges.
Read more →About Regeneron Pharmaceuticals, Inc.
Headquarters777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
BIOPHARMAWATCH ELITE PLUS
Trade the next REGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime